Trauma team activation: which surgical capability is immediately required in polytrauma? A retrospective, monocentric analysis of emergency procedures performed on 751 severely injured patients - Schmitt D, Halvachizadeh S, Steinemann R, Jensen KO, Berk T, Neuhaus V, Mica L, Pfeifer R, Pape HC, Sprengel K.
There has been an ongoing discussion as to which interventions should be carried out by an "organ specialist" (for example, a thoracic or visceral surgeon) or by a trauma surgeon with appropriate general surgical training in polytrauma patients. However, t... (Source: SafetyLit)
Source: SafetyLit - October 15, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

EPA Settles Lawsuits, Agrees to Broader Asbestos Risk Evaluations
Facing legal pressure from health and advocacy organizations, the U.S. Environmental Protection Agency has agreed to broaden its ongoing Risk Evaluation for Asbestos under the Toxic Substances Control Act. An agreement to settle two lawsuits – both alleging inadequate evaluation of toxic asbestos – was filed Oct. 13 in the U.S. Court of Appeals for the Ninth Circuit in San Francisco. The Asbestos Disease Awareness Organization was the lead plaintiff in the risk evaluation litigation and was joined by health organizations, scientists and doctors, including acclaimed thoracic surgeon Dr. Raja Flores of Moun...
Source: Asbestos and Mesothelioma News - October 14, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Patient Gifts Cakes Every Year to Doctor Who Saved His Life Patient Gifts Cakes Every Year to Doctor Who Saved His Life
For the past 15 years, a Rhode Island man has delivered cakes with messages of appreciation to the cardiovascular surgeon who operated on him, thanking him for another year of life.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 7, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021. The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium. “Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Ro...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Science Saturday: A robotic GPS for targeting, delivering regenerative biotherapies
A remote-controlled bronchoscope that acts like a GPS system hunts down hard-to-find lung masses and accurately biopsies them, according to a  Mayo Clinic collaborative study. This multisite research, which is published in Annals of Thoracic Surgery, lays the foundation for precisely finding early-stage cancer and targeting it with regenerative biotherapeutics needed to stimulate healing. Artificial intelligence gleaned from CT scans d irects the robotic fiber optic cable, providing a GPS-like pathway to tiny nodules, or masses, that manual bronchoscopes… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 2, 2021 Category: Databases & Libraries Source Type: news

Study Shows Access to Care Often Difficult for Mesothelioma Patients
When it comes to malignant pleural mesothelioma, not everyone is treated equally. A disparity in access to care makes the difference in mesothelioma treatment quite dramatic, according to the University of Miami’s Sylvester Comprehensive Cancer Center. “Patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease,” medical oncologist Dr. Estelamari Rodriguez told The Mesothelioma Center at Asbestos.com. “The access is not adequate as it should be for everyone.” Rodriguez led a recent study at Univers...
Source: Asbestos and Mesothelioma News - September 28, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cleveland Clinic breaks ground on new hospital
The hospital will initially focus on digestive diseases, general surgery, urology, cardiovascular care, orthopedics, and pulmonary care. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 20, 2021 Category: American Health Authors: Kevin Smith Source Type: news

Assessment of cases of traumatic chest injuries reported to general surgery department - Sonkar SN, Gupta SK.
BACKGROUND: Traumatic injuries are the leading cause of death worldwide. Head and spinal cord injury is the common site of injury followed by thoracic trauma. The present study evaluated various traumatic chest injuries among patients reported to general s... (Source: SafetyLit)
Source: SafetyLit - September 18, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Bypass Is Best Bariatric Surgery to Reduce Cardiovascular Events Bypass Is Best Bariatric Surgery to Reduce Cardiovascular Events
Bariatric surgery is associated with a reduction in risk of major adverse cardiac events, and Roux-en-Y gastric bypass is linked to a greater reduction than sleeve gastrectomy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 16, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

2021 ADAO Asbestos Awareness Conference Runs Sept. 17-18
The 16th Annual International Asbestos Awareness and Prevention Conference takes place Sept. 17-18, featuring 40 speakers from seven countries plus the first-ever Art, Advocacy and Shared Stories film festival. This virtual event is open to all free of charge, requiring only an online registration. It is designed to educate the public about the dangers of asbestos, intensify efforts to ban asbestos, and aid in research to improve treatment for asbestos diseases, including mesothelioma cancer. Sponsoring the event is the Asbestos Disease Awareness Organization, an independent nonprofit regarded as the world’s le...
Source: Asbestos and Mesothelioma News - September 16, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

What Are the Advantages and Disadvantages of Different Renal Replacement Therapies?
Discussion Kidneys are amazing in that they filter the blood, eliminate toxins, balance fluids and electrolytes plus have a lot of reserve to do the job they need to do even when injured. Therefore, depending on the problem, chronic renal disease (CRD) often allows time before renal replacement therapy (RRT) is needed. RRT currently is dialysis (peritoneal or hemodialysis) or renal transplant. In general, the patient’s own kidneys do the best job for them but there is always a balance between the problems of CRD and its management, versus the potentially improved renal function with RRT. RRT itself though has a diffe...
Source: PediatricEducation.org - September 13, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

New Report Details 9/11 Health Effects on FDNY Firefighters
A recent report from the Fire Department of New York World Trade Center Health Program outlines the 9/11-related health effects firefighters are dealing with 20 years later. Approximately 410,000 first responders spent the days and weeks after 9/11 inhaling toxic materials as they helped save lives from the collapse of the Twin Towers. Almost 3,000 people died on Sept. 11, 2001, but in the 20 years since, another 4,343 survivors have died due to related health effects. FDNY has felt the impact of delayed illness, as well. While 343 FDNY firefighters died on 9/11, another 254 have died since then from 9/11-related dis...
Source: Asbestos and Mesothelioma News - September 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Treatment Program Expanding in Central Florida
When he first joined AdventHealth Orlando in 2019, thoracic surgeon Dr. Marcelo DaSilva wondered just how successful he could be in creating a mesothelioma specialty center in Central Florida. Now he knows. DaSilva was initially hoping to create a program that would allow Florida mesothelioma patients to stay closer to home – instead of traveling across the country – and still get the best possible treatment for this rare, tough-to-treat malignancy. But he’s already done considerably more. His vision has grown, and so has his program. More patients will benefit greatly. DaSilva recently expand...
Source: Asbestos and Mesothelioma News - September 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Preoperative CT predicts need for ventilation post-abdominal surgery
Thoracic CT in patients who are slated to undergo abdominal or pelvic surger...Read more on AuntMinnie.comRelated Reading: Specialized CT training helps readers diagnose lung disease PET/CT may predict outcomes in lung cancer surgery ACR releases thoracic CT incidental findings guidance Through COVID-19 pandemic, CT has shown high diagnostic accuracy Rural areas lack access to CT lung cancer screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 3, 2021 Category: Radiology Source Type: news

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease
We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study. Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma. Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients. “Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particu...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mental health of Brazilians heart surgeons: cross-sectional study - Rocha EAV, Araujo FR, Nunes ACM, Khoury LL, Guedes BSM, Pessoa LA, Tolentino DR, Santos ACAB, Magalh ães GL.
INTRODUCTION: Over the past few years, we have seen some signs of change in mental health among cardiovascular surgeons. Suicide cases, troubled professional relationships, separations, and treatment of depression and anxiety are common occurrences in this... (Source: SafetyLit)
Source: SafetyLit - August 16, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Ethicon ’s Echelon Circular Powered Stapler Associated With Major Reduction In Serious Complications Following Colorectal Surgery
Cinncinnati, OH – Aug. 11, 2021 – Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the results of a new real-world study that shows its ECHELON CIRCULAR Powered Stapler was associated with a 74% reduction in anastomotic leak rates (1.8% vs. 6.9%)[1] and a 44% reduction in 30-day inpatient hospital readmission rates (6.1% vs.10.8%) after colorectal surgery compared with manual circular staplers.[2]The study, published in Surgical Endoscopy, shows the groundbreaking device is just as effective in reducing life-threatening and costly surgical complications in real-world surg...
Source: Johnson and Johnson - August 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when combined with aggressive surgery for patients with malignant pleural mesothelioma. Although the U.S. National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the adjuvant radiation – as do many specialists – the Duke research team has challenged the conventional treatment with this report. “The receipt of adjuvant hemithoracic radiation was not associated with improved survival when compared to no radiation,&rdq...
Source: Asbestos and Mesothelioma News - August 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Rwanda: The Adoption of Video-Assisted Technology for Lung Surgery
[New Times] A team of thoracic surgeons from different countries headed by Dr. Diego Gonzalez Rivas had a two-day training visit at King Faisal Hospital (KFH) to introduce a uniportal video-assisted thoracic surgery (VATS) technique in Rwanda. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 8, 2021 Category: African Health Source Type: news

Same-Day Discharge for Elective PCI Safe in Real-World Analysis Same-Day Discharge for Elective PCI Safe in Real-World Analysis
There appears to be no adverse consequences for same-day discharge following an elective percutaneous cardiovascular intervention, analysis of a nationwide registry suggests.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 4, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Coppolino Wins 2021 F. Griffith Pearson Teaching Award
Anthony Coppolino, MD, of the Division of Thoracic and Cardiac Surgery, won the division ’s 2021 F. Griffith Pearson Teaching Award for his outstanding performance as a role model and educator. (Source: BWH News)
Source: BWH News - August 4, 2021 Category: Hospital Management Source Type: news

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Survival after cardiac arrest - Freiburg cardiovascular surgeons develop new technique
(University of Freiburg) German researchers have developed a novel therapeutic approach for resuscitation after cardiac arrest that allows much higher success rates than before - often without neurological complications / Study in Nature Reviews Neuroscience summarizes decisive factors / New „ heart-lung machine " makes clinical implementation possible. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

RNA modification may protect against liver disease, explain liver fat differences between sexes
FINDINGSA chemical modification that occurs in some RNA molecules as they carry genetic instructions from DNA to cells ’ protein-making machinery may offer protection against non-alcoholic fatty liver, a condition that results from a build-up of fat in the liver and can lead to advanced liver disease, according to a new study by UCLA researchers.The study, conducted in mice, also suggests that this modification — known as m6A, in which a methyl group attaches to an RNA chain — may occurat a different ratein femalesthan it does inmales, potentially explaining why females tend to have higher fat content in ...
Source: UCLA Newsroom: Health Sciences - July 19, 2021 Category: Universities & Medical Training Source Type: news

Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub
MELBOURNE, Australia, July 15, 2021 -- Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product developmen...
Source: Johnson and Johnson - July 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Blood Management for Cardiothoracic Surgery: Guidelines Update Blood Management for Cardiothoracic Surgery: Guidelines Update
The Society of Thoracic Surgeons'document, created with multidisciplinary collaboration, includes 23 new or updated recommendations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 7, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Deep learning plus CT helps predict abdominal surgery outcomes
A deep-learning model used with preoperative CT helps predict the complexit...Read more on AuntMinnie.comRelated Reading: Algorithm provides accurate segmentation of pancreas on CT CT, ultrasound provide chance for fatty liver disease screening AI abdominal fat analysis assesses cardiovascular risk AI can opportunistically screen for metabolic syndrome AI plus CT improves liver steatosis assessment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2021 Category: Radiology Source Type: news

Guideline Updated for Blood Management During Heart Surgery
WEDNESDAY, June 30, 2021 -- In a clinical practice guideline update, published online June 30 in the Annals of Thoracic Surgery, recommendations are presented for patient blood management during cardiothoracic surgery. In collaboration with the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bariatric Surgery Leads to Better CV Function in Pregnancy Bariatric Surgery Leads to Better CV Function in Pregnancy
The cardiovascular adaptation of pregnant women after bariatric surgery suggests better hemodynamic function through lower blood pressure, heart rate, and cardiac output, new data show.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 23, 2021 Category: Cardiology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Bariatric Surgery's Cardiovascular Benefit Extends to 7 Years Bariatric Surgery's Cardiovascular Benefit Extends to 7 Years
Patients with obesity who had bariatric surgery had a lower risk of having a major adverse cardiovascular event (MACE) or dying from all causes during a median 7-year follow-up, compared with similar patients who did not undergo surgery.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 22, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Ethicon Expands Advanced Biopolar Energy Portfolio With Launch Of Enseal X1 Curved Jaw Tissue Sealer
CINCINNATI, OH – June 21, 2021 -- Ethicon*, part of the Johnson & Johnson Medical Devices Companies,** today announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency[1] and provided stronger sealing[2] and better access to more tissue than LigaSure™ Maryland.[3] The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures. The ENSEAL X1 Curved Jaw is the first of several new advanced laparoscopic bipolar devices the company plans to launch in the coming months as it expands its extensive ener...
Source: Johnson and Johnson - June 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Women Present With More Advanced Acute Aortic Dissection
MONDAY, June 14, 2021 -- Women with acute aortic dissection are older and have more advanced disease at presentation than men, according to a study published online June 1 in The Annals of Thoracic Surgery. Lauren V. Huckaby, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

WVU Health System adds top pediatric heart expert to lead new center
WVU Health System announced Friday it had hired a pediatric cardiothoracic physician from Children ’s Hospital of Philadelphia to lead its new WVU Medicine Children’s Heart Center. Dr. Christopher E. Mascio will become executive director of the children’s heart center and division chief of pediatric cardiothoracic surgery in the WVU Medicine Department of Cardiovascular and Thoracic Surger y. Mascio is associate clinical chief of the Division of Pediatric Cardiothoracic Surgery and a Cardiac… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 21, 2021 Category: Biotechnology Authors: Paul J. Gough Source Type: news

EPA Facing More Litigation on Legacy Asbestos
The Asbestos Disease Awareness Organization delivered on an earlier notice of intent to sue by filing an official complaint against the U.S. Environmental Protection Agency over its ongoing risk evaluation of asbestos. ADAO, a leading nonprofit aimed at preventing asbestos exposure, was joined by five other organizations and several public health experts in asking the court to set a deadline for the EPA to complete its work. The lawsuit was filed May 18 in the U.S. Northern District of California Court in San Francisco. The notice of intent to sue  was delivered in January. Thoracic surgeon Dr. Raja Flores of Mo...
Source: Asbestos and Mesothelioma News - May 20, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada. Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos. “This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothel...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Pulmonary endarterectomy achieves excellent results for patients with segmental CTEPH
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, found that patients treated surgically for segmental Chronic Thromboembolic Pulmonary Hypertension (CTEPH) had excellent outcomes with the vast majority doing very well in the long term without any additional treatment other than surgery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2021 Category: International Medicine & Public Health Source Type: news